Incyte-Merck trial fails in blow to cancer immunotherapy, but researchers remain hopeful
April 06, 2018 at 15:44 PM EDT
The failure of Incyte's immunotherapy trial in conjunction with a Merck drug deals a blow to immunotherapy, but cancer researchers believe the field still holds potential.